Preclinical data presented at the European Society of Gene and Cell Therapy (ESGCT) highlight a potential best-in-class profile--The AATD ...

A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...

The idea that a single-celled bacterium can defend itself against viruses in a similar way as the 1.8-trillion-cell human ...

In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...

Gene-edited pancreatic cells have been transplanted into a patient with type 1 diabetes for the first time. They produced insulin for months without the patient needing to take immunosuppressants.

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

If you have been staring at CRISPR Therapeutics stock lately, wondering whether it is time to buy, hold, or rethink your position, you are far from alone. Over the past week, the stock has surged 16.1 ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...

Scientists developed a new nanostructure that triples CRISPR’s ability to enter cells, unlocking even more power to treat ...

This year’s WIRED Health summit in Boston featured Moderna CEO Stéphane Bancel, CNN chief medical correspondent Sanjay Gupta, ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving -2.46% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 0.28% for ...